Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Automatic skin lesion segmentation by coupling deep fully convolutional networks and shallow network with textons
56
Zitationen
3
Autoren
2019
Jahr
Abstract
Segmentation of skin lesions is an important step in computer-aided diagnosis of melanoma; it is also a very challenging task due to fuzzy lesion boundaries and heterogeneous lesion textures. We present a fully automatic method for skin lesion segmentation based on deep fully convolutional networks (FCNs). We investigate a shallow encoding network to model clinically valuable prior knowledge, in which spatial filters simulating simple cell receptive fields function in the primary visual cortex (V1) is considered. An effective fusing strategy using skip connections and convolution operators is then leveraged to couple prior knowledge encoded via shallow network with hierarchical data-driven features learned from the FCNs for detailed segmentation of the skin lesions. To our best knowledge, this is the first time the domain-specific hand craft features have been built into a deep network trained in an end-to-end manner for skin lesion segmentation. The method has been evaluated on both ISBI 2016 and ISBI 2017 skin lesion challenge datasets. We provide comparative evidence to demonstrate that our newly designed network can gain accuracy for lesion segmentation by coupling the prior knowledge encoded by the shallow network with the deep FCNs. Our method is robust without the need for data augmentation or comprehensive parameter tuning, and the experimental results show great promise of the method with effective model generalization compared to other state-of-the-art-methods.
Ähnliche Arbeiten
Dermatologist-level classification of skin cancer with deep neural networks
2017 · 13.436 Zit.
Tumor Angiogenesis: Therapeutic Implications
1971 · 10.108 Zit.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
2011 · 7.667 Zit.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
2015 · 5.803 Zit.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2017 · 5.354 Zit.